NCT03769181 2025-09-23A Study of Isatuximab-based Therapy in Participants With LymphomaSanofiPhase 1/2 Terminated58 enrolled 37 charts
NCT06119685 2025-06-03IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic CancersIndapta Therapeutics, INC.Phase 1/2 Recruiting128 enrolled